Assignee: N.V. Innogenetics S.A.

Location: Ghent, BE
No. of patents: 27

Number	Title	Issue Date
8163873	Isolated microtubule-associated protein tau peptides and kit A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a p...	04/24/2012
7855052	Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents The present application discloses and claims polynucleic acids relating to and/or containing HCV polynucleic acid sequences. ...	12/21/2010
7279170	32-kDa protein derived from and related peptides The invention relates to recombinant polypeptides and peptides and particularly to the polypeptide containing in its polypeptidic chain the following amino acid sequence: the one extending from the extremity constituted by nucleotide at position (1) to the extremity...	10/09/2007
7255997	Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 ...	08/14/2007
7195765	Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 ...	03/27/2007
7122306	Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents The present application provides polynucleic acid sequences of 8 or more contiguous nucleotides selected from an HCV subtype 3c genomic sequence selected from the region spanning positions 1 to 957 of the Core of Core/E1 region of HCV subtype 3	10/17/2006
7083797	32-kDa protein derived from and related peptides The invention relates to recombinant polypeptides and peptides and particularly to the polypeptide containing in its polypeptidic chain the following amino acid sequence: the one extending from the extremity constituted by nucleotide at position (1) to the extremity...	08/01/2006
6900293	Monoclonal antibodies directed against the microtubule-associated protein tau A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein ca be obtained from a brain homogenate, itself isolated from the cerebral cortex of a pat...	05/31/2005
6855318	Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes Multimer peptides (e.g. 30- to 45-mer peptides) derived from hepatitis C virus envelope proteins reacting with the majority of anti-HCV antibodies present in patient sera are described. The usage of the latter peptides to diagnose, and to vaccinate against, an infec...	02/15/2005
6709828	PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN A PROCESS FOR DETERMINATION OF ANTIBODIES OR BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM This invention is directed toward a peptide corresponding to an immunologically important viral epitope. Specifically, the peptide corresponds to an immunodominant epitope identified in the envelope region of the human immunodeficiency virus type 1 (HIV-1). This pep...	03/23/2004
6670114	Host derived proteins binding HCV: medical, diagnostic and purification use The finding that the human proteins annexin V, tubulin and apolipoprotein B bind to the hepatitis C virus envelope proteins E1 and/or E2 and the usage of these human proteins to diagnose and treat an infection with hepatitis C virus are described. The usa...	12/30/2003
6667387	HCV core peptides This invention is directed toward a peptide corresponding to an immunologically important viral epitope. Specifically, the peptide corresponds to an immunodominant epitope identified in the gp41 region of the human immunodeficiency virus type 1 (HIV-1), s...	12/23/2003
6656689	Hybridization probes derived from the spacer region between the 16S and 23S rRNA genes for the detection of non-viral microorganisms The invention relates to a probe consisting of at least about 15 nucleotides from the spacer region between rRNA genes of a non-viral organism, particularly prokaryotic organism and more particularly bacteria, and preferably from about 15 nucleotides to a...	12/02/2003
6649735	PROCESS FOR THE DETERMINATION OF PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES AND THEIR USE IN A PROCESS FOR DETERMINATION OF ANTIBODIES OR BIOTINYLATED PEPTIDES CORRESPONDING TO IMMUNOLOGICALLY IMPORTANT EPITOPES, A PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM The technical problem underlying the present invention is to provide peptides corresponding to immunologically important epitopes on bacterial and viral proteins, as well as the use of said peptides in diagnostic or immunogenic compositions. The invention...	11/18/2003
6638511	Mycobacterium polypeptides and nucleic acids encoding them for diagnosis and control of tuberculosis The invention relates to nucleic acids which contain particularly a nucleotide sequence extending from the extremity constituted by the nucleotide at position (1) to the extremity constituted by the nucleotide at position (1211) represented on the figure,...	10/28/2003
6277577	Hybridization probes derived from the spacer region between the 16s and 23s RRNA genes for the detection of non-viral microorganisms The invention relates to a probe consisting of at least about 15 nucleotides from the spacer region between rRNA genes of a non-viral organism, particularly prokaryotic organism and more particularly bacteria, and preferably from about 15 nucleotides to a...	08/21/2001
6245503	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E1/E2 characterized in that upon lysing the transformed host cells to isolate the recom...	06/12/2001
6238892	Monoclonal antibodies directed against the microtubule-associated protein tau A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein ca be obtained from a brain homogenate, itself isolated from the cerebral cort...	05/29/2001
6165730	Hepatitis C virus peptides obtained from the NS4 coding region and their use in diagnostic assays The etiological agent responsible for non-A, non-B hepatitis has been identified and termed hepatitis C virus (HCV). The HCV genome is a linear, positive-stranded RNA molecule with a length of approximately 9,400 nucleotides. With the exception of rather ...	12/26/2000
6110670	Nucleotide sequences, probes and a process for the in vitro diagnosis of chromosomal anomalies correlated with CMT1A disease The invention relates to a process for the in-vitro diagnosis of chromosomal anomalies liable to be correlated with CMT1a disease. The invention also relates to probes intended in this in-vitro diagnosis process and to kits containing said probes. The pro...	08/29/2000
5955356	Nucleic acids, vectors, and host cells including mycobacterium derived sequences The invention relates to nucleic acids which contain particularly a nucleotide sequence extending from the extremity constituted by the nucleotide at position (1) to the extremity constituted by the nucleotide at position (1211) represented on the figure,...	09/21/1999
5945282	Hybridization probes derived from the spacer region between the 16S and 23S rRNA genes for the detection of non-viral microorganisms The invention relates to a probe consisting of at least about 15 nucleotides from the spacer region between rRNA genes of a non-viral organism, particularly prokaryotic organism and more particularly bacteria, and preferably from about 15 nucleotides to a...	08/31/1999
5916558	Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnostic of tuberculosis The invention relates to recombinant polypeptides and peptides which can also be used for the diagnosis of tuberculosis. The invention also relates to a process for preparing the above polypeptides and peptides, which are in a state of biological purity s...	06/29/1999
5891640	Peptide derived from human immunodeficiency virus type 1 (HIV-1), isolate ant70, containing an immunodominant epitope and it's use in immunodiagnostic assays This invention is directed toward a peptide corresponding to an immunologically important viral epitope. Specifically, the peptide corresponds to an immunodominant epitope identified in the gp41 region of the human immunodeficiency virus type 1 (HIV-1), s...	04/06/1999
5891679	TNF-alpha muteins and a process for preparing them The invention relates to tumor necrosis factor muteins characterized in that the TNF-଱ amino acid sequence is mutated, or deleted totally or partially, in the region containing position 101 to 116 in such a way that: either the lectin-like activity ...	04/06/1999
5883238	Process for typing HLA-B using specific primers and probes sets The invention relates to a method for typing or subtyping one or more HLA-B alleles characterized by the sequence GCCA at position 30 to 33 of exon 2 (with said numbering being according to Zemmour and Parham, 1992), liable to be present in a sample, with...	03/16/1999
5866167	Non-viable total keratinocyte lysate for promoting wound healing Cultures of keratinocyte cells are provided which are free from nonautologous fibroblasts and organ extracts, and which have a high speed of cell amplification for a minimum seeding density. Preferably, a culture contains no more than about 10% autologous...	02/02/1999

PatentStorm

Bizarre Patents

PatentStorm News

Assignee: N.V. Innogenetics S.A.